
|Videos|December 28, 2021
Assessing the Potential Adoption of Psychedelic Medicine in Health Care Systems
Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses whether the adoption and acknowledgement of psychedelic medicine in health care systems looks likely for the future.
Advertisement
Pharmacy Times interviewed Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), on psychedelic medicine policy and current advancements in the field.
During the discussion, Ali addressed whether the adoption and acknowledgement of psychedelic medicine within health care systems looks likely for the future.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Cost Avoidance: Advancing Unit-Level Pharmaceutical Economics in Health Systems
2
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
3
Higher Pulmonary Microplastic Burden Observed in Patients With Lung Cancer
4
Pharmacists' Role as Ketone Monitoring Reaches Clinics
5



































































































